Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15535350 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNANPC1KDM4ERAB9A | |
| SCHEMBL15476462 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNANPC1KDM4ERAB9A | |
| SCHEMBL15480774 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNANPC1KDM4ERAB9A | |
| SCHEMBL15480784 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNANPC1KDM4ERAB9A | |
| SCHEMBL8515079 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNANPC1KDM4ERAB9A | |
| SCHEMBL15480781 | 0.89 | TAS1R3 (0.50) | ALDH1A1LMNANPC1KDM4ERAB9A | |
| SCHEMBL15534701 | 0.87 | HTR2B (0.50) | ALDH1A1LMNANPC1KDM4ERAB9A | |
| SCHEMBL15536636 | 0.87 | HTR2B (0.50) | ALDH1A1LMNANPC1KDM4ERAB9A | |
| SCHEMBL15480780 | 0.87 | ALDH1A1 (0.44) | ALDH1A1LMNANPC1KDM4ERAB9A | |
| SCHEMBL15536452 | 0.84 | LIPG (0.50) | ALDH1A1LMNANPC1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458174-B2 | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof | STEMERGIE BIOTECHNOLOGY SA (CH) | 2016-10-04 | — | — | US | claimed |
| US-20150148301-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | Stemergie Biotechnology SA a corporation | 2015-05-28 | — | — | US | claimed |
| EP-2852439-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | Stemergie Biotechnology SA (CH) | 2015-04-01 | — | — | EP | claimed |
| WO-2013174947-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | STEMERGIE BIOTECHNOLOGY SA (CH) | 2013-11-28 | — | — | WO | claimed |
| US-20200188361-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | UNIVERSITE DE MONTREAL (CA) | 2020-06-18 | — | — | US | disclosed |
| US-20190192488-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | Université de Montréal (CA) | 2019-06-27 | — | — | US | disclosed |
| US-9458174-B2 | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof | STEMERGIE BIOTECHNOLOGY SA (CH) | 2016-10-04 | — | — | US | disclosed |
| US-9458174-B2 | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof | STEMERGIE BIOTECHNOLOGY SA (CH) | 2016-10-04 | — | — | US | disclosed |
| US-20150148301-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | Stemergie Biotechnology SA a corporation | 2015-05-28 | — | — | US | disclosed |
| US-20150148301-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | Stemergie Biotechnology SA a corporation | 2015-05-28 | — | — | US | disclosed |
| EP-2852439-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | Stemergie Biotechnology SA (CH) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013174947-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | STEMERGIE BIOTECHNOLOGY SA (CH) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013174947-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | STEMERGIE BIOTECHNOLOGY SA (CH) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188361-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | NPM1, TFAM, NDUFAF1 | ALDH1A1 3326/4885LMNA 837/4885NPC1 2898/4885 |
| US-20150148301-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX (III) OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF | NDUFB3, MT-CO3, SLC25A1 | ALDH1A1 747/4885LMNA 3569/4885NPC1 825/4885 |
| US-20190192488-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | IDH2, TFAM, NUTF2 | ALDH1A1 3227/4885LMNA 1148/4885NPC1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.